Incidents of level 1, level 2 (clinically significant), and level 3 (severe) hypoglycemia, as well as adverse and serious adverse events, were comparable between groups.<h4>Conclusion</h4>Once-weekly insulin efsitora alfa demonstrates comparable efficacy and safety to daily basal insulin. Here, INS is linked to Hypoglycemia.